Back to Search
Start Over
Pharmacokinetics and Pharmacodynamic Effects of Oral GLP-1 and PYY3-36: A Proof-of-concept Study in Healthy Subjects.
- Source :
- Clinical Pharmacology & Therapeutics; Oct2008, Vol. 84 Issue 4, p468-474, 7p, 5 Charts, 6 Graphs
- Publication Year :
- 2008
-
Abstract
- This proof-of-concept study was performed in order to establish the pharmacokinetics and pharmacodynamics of increasing oral doses of the satiety peptides glucagon-like peptide-1 (GLP-1) and peptide YY3-36 (PYY3-36). Six healthy male subjects were given oral doses of either a placebo or GLP-1 in a dose-escalating schedule (doses of 0.5, 1.0, 2.0, and 4.0 mg). Next, another group of six healthy male subjects were given oral doses of either a placebo or PYY3-36 in the same pattern of escalating doses (doses of 0.25, 0.5, 1.0, 2.0, and 4.0 mg). In healthy male volunteers, (i) oral administration of either of the peptides induced a rapid and dose-dependent increase in plasma drug concentrations; (ii) oral administration of GLP-1 induced a potent effect on insulin release; and (iii) both peptides suppressed ghrelin secretion. In conclusion, this study showed, for the first time, that satiety peptides such as GLP-1 and PYY3-36 can be orally delivered safely and effectively in humans.Clinical Pharmacology & Therapeutics (2008); 84, 4, 468–474 doi:10.1038/clpt.2008.35 [ABSTRACT FROM AUTHOR]
- Subjects :
- PHARMACOKINETICS
PHARMACODYNAMICS
PEPTIDES
PHARMACOLOGY
THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 00099236
- Volume :
- 84
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- Clinical Pharmacology & Therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 34360100
- Full Text :
- https://doi.org/10.1038/clpt.2008.35